Dublin, March 02, 2016 -- Research and Markets (http://www.researchandmarkets.com/research/3c2979/proteomics) has announced the addition of Jain PharmaBiotech's new report "Proteomics - Technologies, Markets and Companies" to their offering.
This report describes and evaluates the proteomic technologies that will play an important role in drug discovery, molecular diagnostics and practice of medicine in the post-genomic era - the first decade of the 21st century.
Proteomics is providing a better understanding of pathomechanisms of human diseases. Analysis of different levels of gene expression in healthy and diseased tissues by proteomic approaches is as important as the detection of mutations and polymorphisms at the genomic level and may be of more value in designing a rational therapy.
Protein distribution / characterization in body tissues and fluids, in health as well as in disease, is the basis of the use of proteomic technologies for molecular diagnostics. Proteomics will play an important role in medicine of the future which will be personalized and will combine diagnostics with therapeutics. Important areas of application include cancer (oncoproteomics) and neurological disorders (neuroproteomics). The text is supplemented with 44 tables, 28 figures and over 500 selected references from the literature.
The number of companies involved in proteomics has increased remarkably during the past few years. More than 300 companies have been identified to be involved in proteomics and 223 of these are profiled in the report with 456 collaborations.
The markets for proteomic technologies are difficult to estimate as they are not distinct but overlap with those of genomics, gene expression, high throughput screening, drug discovery and molecular diagnostics. Markets for proteomic technologies are analyzed for the year 2015 and are projected to years 2020 and 2025. The largest expansion will be in bioinformatics and protein biochip technologies. Important areas of application are cancer and neurological disorders.
Key Topics Covered:
Part I: Technologies & Markets
1. Basics of Proteomics
2. Proteomic Technologies
3. Protein biochip technology
4. Bioinformatics in Relation to Proteomics
5. Research in Proteomics
6. Pharmaceutical Applications of Proteomics
7. Application of Proteomics in Human Healthcare
8. Oncoproteomics
9. Neuroproteomics
10. Proteomics Markets
11. Future of Proteomics
12. References
Part II: Companies
11. Companies involved in developing proteomics
For more information visit http://www.researchandmarkets.com/research/3c2979/proteomics
Source: Jain PharmaBiotech
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Proteomics


European Car Sales Surge in March as EV and Hybrid Demand Accelerates
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion
Meta Expands AI Training With Employee Activity Tracking Tools
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 



